DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Nov 5, 3:06 PM·
Medium Optimistic
Summary
Denali Therapeutics (DNLI) shares rose 7.8% following its Q3 earnings report, driven by Avlayah sales that surged nearly fivefold. The company also cited expanding reimbursement coverage and multiple approaching pipeline catalysts.
Denali Therapeutics Shares Rise 7.8% After Q3 Earnings
Denali Therapeutics (DNLI) shares gained 7.8% following the company’s third-quarter earnings report, according to Zacks.
Avlayah Sales Surge
The move came as sales of Avlayah surged nearly fivefold, the report said.
Reimbursement Coverage Expands
Denali also cited expanding reimbursement coverage for its product, according to the report.
Pipeline Catalysts Ahead
The company pointed to multiple pipeline catalysts approaching, Zacks reported.
The source material did not disclose specific revenue figures, coverage details or the timing of the cited catalysts.